Global Business Development
We’re accelerating our external innovation efforts – advancing differentiated science through bold partnerships with the shared ambition to improve patient lives.
Innovation is a team sport. We show up in the world’s leading biotech ecosystems where new ideas take shape and where collaboration accelerates progress.
At Daiichi Sankyo, we pursue science that strengthens our oncology leadership, complements our pipeline, and expands what’s possible through emerging platforms and research technologies. Rooted in disciplined scientific inquiry and a legacy of innovation, we bring cross-functional expertise, from bio-modalities and pharmacology to advanced data science, built on the deep capabilities shaped by our DXd ADC platform.
We tailor collaboration models to the needs of each asset and partner, leveraging our global R&D network to connect potential partners with the right experts and help promising science move forward faster.
“Innovation doesn’t happen in isolation. We seek partners who share our commitment to advancing science with integrity, curiosity, and courage.”
– Stu Mackey, Global Head of Business Development, Daiichi Sankyo
Scientific Areas of Interest
- Early clinical assets or late preclinical in Breast, Lung and Colorectal Cancer
- Non-oncology, late-stage assets (Phase 2 ongoing or later) Regional Partnerships
- Immunology, Cardiovascular, CNS Diseases
Target areas, focusing on novel disease-relevant target identification research by using patient tissue samples or genetic analysis for the following target diseases
- Oncology: novel, unique, biologically tractable, tumor-associated antigens
- Immunology: refractory immune diseases and lung fibrosis
- Cardiovascular and Metabolic: heart failure, MASH (not TG reducer)
- CNS Diseases: neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, multiple system atrophy, and ALS and psychiatric diseases such as Schizophrenia
- Ophthalmology: AMD, RP, and PDR
Preferred modalities: Targeted Protein Degrader, Molecular Glue, RNA-targeting small molecules, siRNA delivery systems, bispecific/multi-specific antibodies and engineered protein technology platforms
- Targeted Protein Degraders: Novel targeted protein degradation technologies such as tumor/tissue selective E3 ligases (other than CRBN, VHL, IAP or MDM2) and degradation mechanisms other than ubiquitin proteasome system (UPS)
- Molecular Glue: Novel methods for rational discovery of molecular glues in oncology and CNS
- RNA-targeting small molecule technologies: Novel strategies to modify translation, splicing, or other functionally relevant discovery methods
- siRNA delivery systems: delivery with priority for BBB-penetrant methods
- Bispecific/multi-specific antibodies and engineered protein technology platforms: Technologies enabling functional or proximity-based bispecifics and engineered proteins with improved tumor selectivity and therapeutic index, including NKCE and TCE platforms
- ADC: focus on highly tumor specific targets and methods of discovering them
Modality agnostic asset enabling technologies: Binders or strategies for identifying novel, unique, biologically tractable, tumor-associated antigens, tumor microenvironment modulators, AI drug discovery
- Binders for novel, unique, biologically tractable, tumor-associated antigens: in single or multi-modal formats with improved therapeutic properties
- Tumor microenvironment modulators: e.g. TME-responsive biologics
- AI drug discovery: e.g. De novo design of protein-based binders
- Single cell proteomics, RNA-seq, and CTC biomarker based strategies
- Preclinical models for areas such as immune checkpoint inhibitor refractory tumors
Connected to Whats Next
Our search & evaluation, transactions, alliance management, and strategic initiatives teams work closely within our Global Business Development organization to create a smooth, coordinated experience for partners from early discussions through long-term collaboration. Our approach is grounded in transparency, flexibility, and shared purpose, inspired by the Japanese principle of sanpo-yoshi: good for you, good for us, and good for patients.
With team members across Japan, the United States, Europe, and China and deep collaboration with our Research Institutes in Boston, Munich, and San Diego, we stay embedded in major innovation hubs around the world. These connections strengthen our ability to build strategic partnerships and accelerate promising science.
Tell us about your science.
Please submit your non-confidential licensing or alliance proposal for consideration
